الصفحة الرئيسية>>NTRC 0066-0

NTRC 0066-0

رقم الكتالوجGC62259

NTRC 0066-0 هو مثبط انتقائي للثريونين التيروزين كيناز (TTK) (IC50 = 0.9 نانومتر)يمكن استخدام NTRC 0066-0 لأبحاث السرطان

Products are for research use only. Not for human use. We do not sell to patients.

NTRC 0066-0 التركيب الكيميائي

Cas No.: 1817791-73-3

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
202٫00
متوفر
5 mg
162٫00
متوفر
10 mg
261٫00
متوفر
25 mg
522٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com


مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

NTRC 0066-0 is a selective threonine tyrosine kinase (TTK) inhibitor (IC50=0.9 nM). NTRC 0066-0 can be used for the research of cancer[1].

NTRC 0066-0 has a low selectivity entropy and a relatively long target residence time on TTK and inhibits the proliferation of diverse cancer cell lines with a potency in the same range as that of classic chemotherapeutic agents such as doxorubicin. NTRC 0066-0, has subnanomolar potency in a TTK enzyme assay and inhibits the proliferation of cancer cell lines from diverse tumor tissue origin with IC50 from 11 to 290 nM at 5-day incubation time[1].

NTRC 0066-0 inhibited tumor growth in a mouse xenograft model of the human triple-negative breast cancer (TNBC) cell line MDA-MB-231[1].

[1]. Uitdehaag JCM, et al. Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity. J Mol Biol. 2017;429(14):2211-2230.

مراجعات

Review for NTRC 0066-0

Average Rating: 5 ★★★★★ (Based on Reviews and 18 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for NTRC 0066-0

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.